Status of glucose metabolism in patients with heart failure secondary to coronary artery disease.
Cardiac Rehabilitation Institute, Tel-Aviv, Israel. altenen@yahoo.com
Alexander
A
Tenenbaum
Michael
M
Motro
Enrique Z
EZ
Fisman
Jonathan
J
Leor
Valentina
V
Boyko
Lori
L
Mandelzweig
Solomon
S
Behar
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism*; D006333:Heart Failure / Q000209:etiology* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D015995:Prevalence; D016019:Survival Analysis; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D005947:Glucose